


WHAT IS CLAIMED:

1. A 3-deoxy-D-myo-inositol analog having the formula:



wherein X is O or CH₂; R¹ and R² are individually, (C₁-C₂₅) alkyl, (C₆-C₁₀) aryl, (C₃-C₈) cycloalkyl, (C₂-C₂₂) alkenyl, (C₅-C₈) cycloalkenyl, (C₇-C₃₂) aralkyl, (C₇-C₃₂) alkylaryl, (C₉-C₃₂) aralkenyl, (C₉-C₃₂) alkenylaryl or C(O)R³; and R³ is (C₁-C₂₅) alkyl, (C₆-C₁₀) aryl, (C₃-C₈) cycloalkyl, (C₂-C₂₂) alkenyl, (C₅-C₈) cycloalkenyl, (C₇-C₃₂) aralkyl, (C₇-C₃₂) alkylaryl, (C₉-C₃₂) aralkenyl or (C₉-C₃₂) alkenylaryl; R⁴ and R⁵ are individually hydrogen or a phosphate group; or when R⁴ or R⁵ is not hydrogen, a pharmaceutically acceptable salt thereof.

2. (Once Amended) A method of treating cancer comprising administering a therapeutically effective amount of a compound to a subject according to claim 1.
3. The method of Claim 2, wherein said cancer is one that is characterized by cells that over-express the EGF and/or the PDGF receptor, cells that express a mutant ras, or cells that comprise a Bcr/Abl transfection.
4. The method of Claim 3, wherein said cancer is selected from the group consisting of colon, pancreatic, prostate, head and neck, breast, gastric, renal, brain and CML.